• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to previous page

Individualized therapy of patients with leukemia based on WT1 assay.

Research Project

Project/Area Number 11670995
Research Category

Grant-in-Aid for Scientific Research (C)

Allocation TypeSingle-year Grants
Section一般
Research Field Hematology
Research InstitutionOsaka University

Principal Investigator

HIROYASU Ogawa  Osaka University Graduate School of Medicine, Associate Professor, 医学系研究科, 助教授 (80194447)

Co-Investigator(Kenkyū-buntansha) YUSUKE Oji  Osaka University Medical School, Associate Professor, 医学部, 助手 (20294100)
TOSHIHIRO Soma  Osaka University Graduate School of Medicine, Associate Professor, 医学系研究科, 助手 (40273619)
YOSHIHIRO Oka  Osaka University Graduate School of Medicine, Associate Professor, 医学系研究科, 助手 (20273691)
坪井 昭博  大阪大学, 医学部・附病院, 医員
AKIHIRO Tsuboi  Osaka University Hospital, Medical Staff
立川 豊吏  大阪大学, 医学部・附属病院, 医員
Project Period (FY) 1999 – 2000
Project Status Completed (Fiscal Year 2000)
Budget Amount *help
¥3,100,000 (Direct Cost: ¥3,100,000)
Fiscal Year 2000: ¥1,500,000 (Direct Cost: ¥1,500,000)
Fiscal Year 1999: ¥1,600,000 (Direct Cost: ¥1,600,000)
Keywordsleukemia / minimal residual disease / WT1 / bone marrow transplantation / 微小残存白血病 / キメラ遺伝子
Research Abstract

We have reported that a high expression of WT1 gene is observed in almost all patients with leukemia, and that the detection of minimal residual disease (MRD) can be done in a sensitivity of 10^<-3> to 10^<-5> by the quantitation of WT1 gene expression levels on real-time PCR method. A low level of WT1 gene expression which is observed in CD34+ cells have been found to result in the background level expression of WT1 in bone marrow specimens. In this present study, the background levels of WT1 gene expression was found to reduce in one order in patients after bone marrow transplantation (BMT), by analyzing the WT1 gene expression in bone marrow samples in. which chimeric gene expressions could not be detected in RT-PCR analysis. These findings indicate that the sensitivity to detect MRD was increased after BMT.Furthermore, in the analysis of WT1 levels in patients who underwent BMT, a low level of WT1 gene expression before BMT, the HLA disparity between donors and recipients, and the presence of clinical graft-versus-host disease were found to be good prognostic factors to obtain a continuous complete remission.

Report

(3 results)
  • 2000 Annual Research Report   Final Research Report Summary
  • 1999 Annual Research Report
  • Research Products

    (18 results)

All Other

All Publications (18 results)

  • [Publications] Tsuboi,A. el al.: "Constitutive expression of the Wilms'tumor gene WT1 inhibits the differentiation of myeloid progenitor cells but promotes their proliferation in response to granulocyte-colony stimulating factor (G-CSF)."Leukemia Research.. 23. 499-505 (1999)

    • Description
      「研究成果報告書概要(和文)」より
    • Related Report
      2000 Final Research Report Summary
  • [Publications] Oji,Y. et al.: "Expression of the Wilms'tumor gene WT1 in solid tumors and its involvement in tumor cell growth."Japanese Journal of Cancer Research.. 90. 194-204 (1999)

    • Description
      「研究成果報告書概要(和文)」より
    • Related Report
      2000 Final Research Report Summary
  • [Publications] 0ka,Y. et al.: "Human cytotoxic T lymphocyte responses specific for peptides of wild-type Wilms'tumor gene WT1 product."Immunogenetics.. 51. 99-107 (2000)

    • Description
      「研究成果報告書概要(和文)」より
    • Related Report
      2000 Final Research Report Summary
  • [Publications] Oka,Y. et al.: "Cancer immunotherapy targeting Wilms'tumor gene WT1 product."Journal of Immunology.. 164. 1873-1880 (2000)

    • Description
      「研究成果報告書概要(和文)」より
    • Related Report
      2000 Final Research Report Summary
  • [Publications] Tsuboi,A. et al.: "Cytotoxic T lymphocyte responses elicited to Wilms'tumor gene WT1 product by DNA vaccination."Journal of Clinical Immunology.. 20. 195-202 (2000)

    • Description
      「研究成果報告書概要(和文)」より
    • Related Report
      2000 Final Research Report Summary
  • [Publications] Tsuboi, A, et al.: "Constitutive expression of the Wilms' tumor gene WT1 inhibits the differentiation of myeloid progenitor cells but promotes their proliferation in response to granulocyte-colony stimulating factor (G-CSF)."Leukemia Research. 23. 499-505 (1999)

    • Description
      「研究成果報告書概要(欧文)」より
    • Related Report
      2000 Final Research Report Summary
  • [Publications] Oji, Y, et al.: "Expression of the Wilms' tumor gene WT1 in solid tumors and its involvement in tumor cell growth."Japanese Journal of Cancer Research. 90. 194-204 (1999)

    • Description
      「研究成果報告書概要(欧文)」より
    • Related Report
      2000 Final Research Report Summary
  • [Publications] Oka, Y, et al.: "Human cytotoxic T lymphocyte responses specific for peptides of wild-type Wilms' tumor gene WT1 product."Immunogenetics. 51. 99-107 (2000)

    • Description
      「研究成果報告書概要(欧文)」より
    • Related Report
      2000 Final Research Report Summary
  • [Publications] Oka, Y, et al.: "Cancer immunotherapy targeting Wilms' tumor gene WT1 product."Journal of Immunology. 164. 1873-1880 (2000)

    • Description
      「研究成果報告書概要(欧文)」より
    • Related Report
      2000 Final Research Report Summary
  • [Publications] Tsuboi, A, et al.: "Cytotoxic T lymphocyte responses elicited to Wilms' tumor gene WT1 product by DNA vaccination."Journal of Clinical Immunology. 20. 195-202 (2000)

    • Description
      「研究成果報告書概要(欧文)」より
    • Related Report
      2000 Final Research Report Summary
  • [Publications] Tsuboi,A. et al.: "Constitutive expression of the Wilms' tumor gene WT1 inhibits the differentiation of myeloid progenitor cells but promotes their proliferation in response to granulocyte-colony slimulating factor (G-CSF)."Leukemia Research.. 23. 499-505 (1999)

    • Related Report
      2000 Annual Research Report
  • [Publications] Oji,Y. et al.: "Expression of the Wilms' tumor gene WT1 in solid tumors and its involovement in tumor cell growth."Japanese Journal of Cancer Research.. 90. 194-204 (1999)

    • Related Report
      2000 Annual Research Report
  • [Publications] Oka,Y. et al.: "Human cytotoxic T lymphocyle responses specific for peptides of wild-type Wilms' tumor gene WT1 product."Immunogenetics.. 51. 99-107 (2000)

    • Related Report
      2000 Annual Research Report
  • [Publications] Oka,Y. et al.: "Cancer immunotherapy targeting Wilms' tumor gene WT1 product."Journal of Immunology.. 164. 1873-1880 (2000)

    • Related Report
      2000 Annual Research Report
  • [Publications] Tsuboi,A. et al.: "Cytotoxic T lymphocyle responses elicited to wilms' tumor gene WT1 product by DNA vaccination."Journal of Clinical Immunology.. 20. 195-202 (2000)

    • Related Report
      2000 Annual Research Report
  • [Publications] Tamaki H.et al.: "The Wilms' tumor gene WT1 is a good marker for diagnosis of disease progression of myelodyspastic syndromes"Leukemia. 13. 393-399 (1999)

    • Related Report
      1999 Annual Research Report
  • [Publications] Oji Y.et al.: "Expression of the Wilms' tumor gene WT1 in solid tumors and its involvement in tumor cell growth"Jpn. J. Cancer Research. 90. 194-204 (1999)

    • Related Report
      1999 Annual Research Report
  • [Publications] Oka Y.et al.: "Cancer immunotherapy trageting Wilms' tumor gene WT1 product"J. Immunol.. 164. 1873-1880 (2000)

    • Related Report
      1999 Annual Research Report

URL: 

Published: 1999-04-01   Modified: 2016-04-21  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi